Neurovision Pharma GmbH
Records under this name other than the patents Neurovision Pharma GmbH holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 2 patents it holds.
Showing 1 to 5 of 5 · Back to Neurovision Pharma GmbH
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,785,601 | Methods of treating neurological conditions with hematopoietic growth factors Lapsed on the fee record Ended Aug 31, 2022 · USPTO record | Lapsed on the fee record | Ended Aug 31, 2022 | USPTO record |
| US 8,071,543 | Methods of treating neurological conditions with hematopoeitic growth factors Lapsed on the fee record Ended Dec 6, 2019 · USPTO record | Lapsed on the fee record | Ended Dec 6, 2019 | USPTO record |
| US 8,053,407 | Methods of treating neurological conditions with hematopoeitic growth factors Lapsed on the fee record Ended Nov 8, 2019 · USPTO record | Lapsed on the fee record | Ended Nov 8, 2019 | USPTO record |
| US 7,884,069 | Methods of treating neurological conditions with hematopoeitic growth factors Lapsed on the fee record Ended Feb 8, 2019 · USPTO record | Lapsed on the fee record | Ended Feb 8, 2019 | USPTO record |
| US 7,695,723 | Methods of treating neurological conditions with hematopoietic growth factors Lapsed on the fee record Ended Apr 13, 2018 · USPTO record | Lapsed on the fee record | Ended Apr 13, 2018 | USPTO record |